SlideShare uma empresa Scribd logo
1 de 32
Baixar para ler offline
Nasopharyngeal Brachytherapy
Dr. Ashutosh Mukherji
Associate Professor
Department of Radiotherapy,
Regional Cancer Centre, JIPMER
INTRODUCTION
• Cancer of the nasopharynx is relatively uncommon in Western
countries (0.5-2/1,00,000/yr), but more frequent in parts of Asia
(30-80/1,00,000/yr) and North Africa (8-12/100,000/yr).
• Mostly Inoperable, spread early to cervical lymph nodes, distant
metastases is fairly well known.
• Main prognosis factors are the local extension of the tumours
(invasion of the base of skull and paralysis of the cranial nerves)
and lymph node metastasis.
2
ANATOMY…….
3
• The nasopharyngeal cavity
communicates anteriorly with
the nasal cavities through the
choanae and inferiorly with the
oropharynx.
• The sphenoid body limits it
superiorly, the first two
vertebrae posteriorly, and the
soft palate inferiorly.
• The Eustachian tubes open into
its lateral walls, in front of the
fossa of Rosenmüller.
INDICATIONS
• Brachytherapy applications of the nasopharynx are restricted to
– Boost for minimal residual local disease after external
irradiation
– Salvage therapy for well-circumscribed and superficial local
recurrences limited to the nasopharyngeal cavity without
involvement of the underlying bone or extending to
oropharynx or nasal cavities
4
• Nasopharynx deeply situated and surrounded by bone,
vessels and nerves  usually endocavitary techniques can be
performed.
• CTV thickness should not exceed 10 mm
• Tumours extending into the nasal cavities or the oropharynx
should not be accepted for brachytherapy.
5
TARGET VOLUME
• The PTV defined by
endoscopy, CT-Scan and
MRI.
• Most tumours are
situated at the roof of
the nasopharynx.
6
In central tumours, the CTV may include both roof and lateral walls.
In well-lateralised tumours, CTV will include the roof and one lateral
wall. In most cases, the depth of PTV does not exceed 10 mm.
TECHNIQUES APPLIED
• CUSTOMISED MOULD
• ROTTERDAM
NASOPHARYNGEAL
APPLICATOR
• MASSACHUSETTS GENERAL
HOSPITAL TECHNIQUE
• TRANSNASAL PERMANENT
INTERSTITIAL IMPLANTS
7
CUSTOMISED MOULD
TECHNIQUE
• Sagittally oriented plastic tubes are fixed on the surface of a rigid acrylic
applicator, made from an individual impression of the nasopharyngeal
cavity.
• Procedure is therefore performed under neuroleptic analgesia
• Nasal secretions are suctioned and the mucous membranes anaesthetised
with 5% xylocaine spray to avoid gag reflex or pain.
• First rubber catheters are passed through both nostrils and brought out of
the mouth; the oral ends of these are tied to a dummy applicator coated
with silicone paste.
8
• This paste coated dummy applicator is pulled into the nasopharynx and
paste forms an impression of the naspharyngeal cavity.
• Then from this impression a negative POP mould is prepared from which
the actual acrylic mould is made with 2-5 mm thick walls.
• Boundaries of the tumour are highlighted in ink and source position that
will provide optimal coverage of the lesion are indicated with sagittal
lines.
• Spacing between sources varies from 10 to 15 mm. In average patients,
the rule for catheter implantation is 2 catheters per wall or 3 catheters for
2 walls or 4 catheters for 3 walls (roof and 2 walls)
9
10
ROTTERDAM APPLICATOR
• Is made of soft silicone
• Well tolerated by patient
• Insertion procedure is same as for
customised mould
• The applicator can remain in situ
for the duration of the treatment,
from 2 to 6 days.
• The two silicone tubes, can
accommodate standard 6 French
afterloading catheters.
• The legs of the applicator sort
through the nostrils and are fixed
with a silicone bridge, pushed
against the nasal septum.
11
12
MASSACHUSETTS GENERAL
HOSPITAL TECHNIQUE
• This technique uses two paediatric endotracheal tubes with inner and
outer diameter of 5 and 6.8 mm, respectively. They can be afterloaded
each with 20-mg radium-equivalent caesium 137 slugs or stepping source
PDR or HDR afterloaders.
• After topical anaesthesia endotracheal tubes are introduced into the
nasopharynx through the nostrils and under fluoroscopic control, the
distal tip of the dummy sources are placed at the free edge of the soft
palate posteriorly and at the posterior wall of the maxillary sinus
anteriorly.
• An inflated balloon, attached to the distal end of the endotracheal tube,
is used to anchor the tubes and to create a distance between the
radiation sources and the nasopharyngeal vault to obtain a better depth
dose.
13
TRANSNASAL PERMANENT
INTERSTITIAL IMPLANTS
• Using fibre-optic endoscopy and under direct visualisation, hollow after-
loading needles are introduced into the nasal passages and are advanced
through the posterior choanae, and inserted into the mucosal surface.
• Radioactive I-125 seeds are then introduced submucosally through these
needles, and the needles are withdrawn.
14
• The dose prescribed to an isodose covering the surface of the
underlying bone, at 5 - 10 mm from the mucosal surface.
• Dose distribution optimized when possible so that the reference
isodose follows the bone surface.
15
• Brachytherapy used to deliver BOOST dose to a small volume after a full
course of external beam radiation therapy.
• In LDR brachy, the active source is tailored to the nasopharynx proper that
is to the distance between the ‘Node of Rouviere’ (at the level of the C-I
vertebral body) and the pterygoid plates. The Ir-192 source is removed
after a dose of 11 Gy is delivered to the nasopharynx “tumour tissue” (TT)
point.
• For HDR, a boost dose of 9 Gy in 3 fractions of 3 Gy each is delivered with a
minimum interval of 6 hours between fractions prescribed as described in
previous slides.
16
DOSES PRESCRIBED
• Wang delivered with LDR afterloading intracavitary implant 7 - 12 Gy at 5
mm below the mucosa.
• Levendag et al. deliver after a rest period of 1 - 2 weeks, a boost dose to
the primary site with HDR brachytherapy, with two 3 Gy fractions per day
at 6 hour interval. Total of fractions is 6 (after 60 Gy external beam
irradiation) for T1 - 3 tumours, and 4 (after 70 Gy external beam
irradiation) for T4 tumours.
• For recurrent tumour recurring, 60 Gy is delivered in roughly 6 days with a
LDR technique
17
18
RESULTS
• Since 1974, at Massachusetts General Hospital, afterloading intracavitary
implant has been carried out as a routine procedure to deliver a dose of 7-
12 Gy as a boost to the nasopharynx for most T1 and T2 and occasionally
T3 lesions
19
5 year survival rates in MGH
in nasopharyngeal cancers
RESULTS
• At Rotterdam, in a prospective study of 41 patients treated with 60-70 Gy
external beam radiation therapy and 12 - 18 Gy HDR brachytherapy boost,
the 5-year local relapse free survival rate of T1 - 2 cancer patients (n = 29)
was 96% versus 57% for T4 cancer patients (n = 12) (p = 0.002)
20
5 year actuarial survival rates in MGH in recurrent
nasopharyngeal cancers
21
RESULTS
22
RESULTS
23
RESULTS
24
RESULTS
• 18–24% of patients with nasopharyngeal carcinoma develop local recurrences
• Brachytherapy is an important modality for treatment of localised small
recurrences.
• Other modalities are:
– Cyberknife RadioSurgery
– SBRT
– IMRT
• The period elapsed before development of local recurrence is a significant
factor influencing disease-free survival times.
25
Causes of relapse in Ca Nasopharynx
Failure= 192/610 (31%)
Local Failure ONLY= 52%
Distance metastasis=27%
Death= 156/610
Cause of death:
Local Relapse only= 44%
Distance mets= 28%
Local control after relapse improves survival
Sun JA et al, Asian Pacific J 2007
Surgery for Rec Nasopharynx
- ONLY few prospective reports
- Skull base/ bone erosion & carotid artery erosion not considered for surgery
- 5-Yr OS: 40-60%
- 20% palatal fistula
28
Liu et al. Radiation Oncology 2013
SBRT: persistent Nasopharyngeal Ca
-No difference in maximum spinal cord dose and mean parotid doses between
HDR & CK boost plans; In IMRT plan, higher ipsi-lateral parotid dose
Comparison of three plans (Dose: 24
Gy/6#)
IMRT boost HDR boost CK boost
Spinal cord Dmax
(Gy)
7.4 1.2 1.5
Ipsi-lateral parotid
Mean dose
(Gy)
8.3 3.1 2.1
Conta-lateral parotid
Mean dose
(Gy)
3.7 1.4 1.7
(n=11) Dutta et al; CK Society meeting San Francisco 2010
31
• Study from Hong Kong
• 34 patients with locally persistent NPC who were treated during 1992–2000
with HDR intracavitary brachytherapy were analyzed retrospectively. All
patients had T2b disease at initial diagnosis.
• An improvement in the 5-year actuarial local failure-free survival rate
(brachytherapy group vs. ERT group: 96.9% vs. 81.5%; P 0.024), the disease
specific survival rate (84.5% vs. 68.1%; P 0.021), and the overall survival rate
(78.3% vs. 63.1%; P 0.034) was seen in the group with locally persistent NPC
salvaged with brachytherapy.
THANK YOUTHANK YOU

Mais conteúdo relacionado

Mais procurados

Radiotherapy techniques, indications and evidences in oral cavity and oropha...
Radiotherapy techniques, indications and evidences  in oral cavity and oropha...Radiotherapy techniques, indications and evidences  in oral cavity and oropha...
Radiotherapy techniques, indications and evidences in oral cavity and oropha...Dr.Amrita Rakesh
 
RE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCERRE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCERMUNEER khalam
 
Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions Anil Gupta
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancerDrAyush Garg
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiationKanhu Charan
 
Radiotherapy in ca esophagus
Radiotherapy in ca esophagusRadiotherapy in ca esophagus
Radiotherapy in ca esophagusIsha Jaiswal
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiationKanhu Charan
 
2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMOR2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMORKanhu Charan
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancerfondas vakalis
 
Quantec dr. upasna saxena (2)
Quantec   dr. upasna saxena (2)Quantec   dr. upasna saxena (2)
Quantec dr. upasna saxena (2)Upasna Saxena
 
MOULD BRACHYTHERAPY
MOULD BRACHYTHERAPYMOULD BRACHYTHERAPY
MOULD BRACHYTHERAPYKanhu Charan
 
BOOK ON REIRRADIATION
BOOK ON REIRRADIATIONBOOK ON REIRRADIATION
BOOK ON REIRRADIATIONKanhu Charan
 
Stereotactic radiosurgery and radiotherapy
Stereotactic radiosurgery and radiotherapyStereotactic radiosurgery and radiotherapy
Stereotactic radiosurgery and radiotherapyumesh V
 
Adaptive radiotherapy in head and neck cancer
Adaptive radiotherapy in head and neck cancerAdaptive radiotherapy in head and neck cancer
Adaptive radiotherapy in head and neck cancerDr. Rituparna Biswas
 
Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapyfondas vakalis
 

Mais procurados (20)

Radiotherapy techniques, indications and evidences in oral cavity and oropha...
Radiotherapy techniques, indications and evidences  in oral cavity and oropha...Radiotherapy techniques, indications and evidences  in oral cavity and oropha...
Radiotherapy techniques, indications and evidences in oral cavity and oropha...
 
RE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCERRE-IRRADIATION IN HEAD AND NECK CANCER
RE-IRRADIATION IN HEAD AND NECK CANCER
 
Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiation
 
Radiotherapy in ca esophagus
Radiotherapy in ca esophagusRadiotherapy in ca esophagus
Radiotherapy in ca esophagus
 
Altered fractionation kiran
Altered fractionation   kiranAltered fractionation   kiran
Altered fractionation kiran
 
Hypofractionation in breast cancer
Hypofractionation in breast cancerHypofractionation in breast cancer
Hypofractionation in breast cancer
 
Hypofractionation in hnc
Hypofractionation in hncHypofractionation in hnc
Hypofractionation in hnc
 
Total body irradiation
Total body irradiationTotal body irradiation
Total body irradiation
 
Approach towards reirradiation
Approach towards reirradiationApproach towards reirradiation
Approach towards reirradiation
 
2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMOR2D PLANNING IN BRAIN TUMOR
2D PLANNING IN BRAIN TUMOR
 
TBI
TBITBI
TBI
 
Radiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung CancerRadiotherapy For Non Small Cell Lung Cancer
Radiotherapy For Non Small Cell Lung Cancer
 
Quantec dr. upasna saxena (2)
Quantec   dr. upasna saxena (2)Quantec   dr. upasna saxena (2)
Quantec dr. upasna saxena (2)
 
MOULD BRACHYTHERAPY
MOULD BRACHYTHERAPYMOULD BRACHYTHERAPY
MOULD BRACHYTHERAPY
 
BOOK ON REIRRADIATION
BOOK ON REIRRADIATIONBOOK ON REIRRADIATION
BOOK ON REIRRADIATION
 
Stereotactic radiosurgery and radiotherapy
Stereotactic radiosurgery and radiotherapyStereotactic radiosurgery and radiotherapy
Stereotactic radiosurgery and radiotherapy
 
Adaptive radiotherapy in head and neck cancer
Adaptive radiotherapy in head and neck cancerAdaptive radiotherapy in head and neck cancer
Adaptive radiotherapy in head and neck cancer
 
Stereotactic Body Radiation Therapy
Stereotactic Body Radiation TherapyStereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy
 

Semelhante a Nasopharyngeal brachytherapy

Management Carcinoma Nose & PNS
 Management Carcinoma Nose & PNS Management Carcinoma Nose & PNS
Management Carcinoma Nose & PNSSatyajeet Rath
 
Ca Maxilla - Radiation Therapy
Ca Maxilla - Radiation Therapy Ca Maxilla - Radiation Therapy
Ca Maxilla - Radiation Therapy Aaditya Sinha
 
Ca external and middle ear staging to management1
Ca external and middle ear staging to management1Ca external and middle ear staging to management1
Ca external and middle ear staging to management1Dr Durgesh Kumar
 
Lacrimal sac surgery
Lacrimal sac surgeryLacrimal sac surgery
Lacrimal sac surgerySSSIHMS-PG
 
journal presentation on traumatic Tympanic membrane perforations.pptx
journal presentation on traumatic Tympanic membrane perforations.pptxjournal presentation on traumatic Tympanic membrane perforations.pptx
journal presentation on traumatic Tympanic membrane perforations.pptxAkanshaVerma97
 
JC PRESENTATION.pptx journey of a oh yeahh
JC PRESENTATION.pptx journey of a oh yeahhJC PRESENTATION.pptx journey of a oh yeahh
JC PRESENTATION.pptx journey of a oh yeahhDiveshJain32
 
Salivary gland tumors
Salivary gland tumors Salivary gland tumors
Salivary gland tumors Nilesh Kucha
 
Head Neck Interstitial Brachy.pptx
Head Neck Interstitial Brachy.pptxHead Neck Interstitial Brachy.pptx
Head Neck Interstitial Brachy.pptxSayan Das
 
MOULD BRACHYTHERAPY LIP
MOULD BRACHYTHERAPY LIPMOULD BRACHYTHERAPY LIP
MOULD BRACHYTHERAPY LIPKanhu Charan
 
Seminar on para nasal sinus and it's prosthodontics implications
Seminar on para nasal sinus and it's prosthodontics implications Seminar on para nasal sinus and it's prosthodontics implications
Seminar on para nasal sinus and it's prosthodontics implications Dr Aditi Shreya
 
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...komalicarol
 
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGY
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGYCARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGY
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGYPaul George
 
Radiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumoursRadiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumoursAshutosh Mukherji
 
High intensity Focused Ultrasound / HIFU
High intensity Focused Ultrasound / HIFUHigh intensity Focused Ultrasound / HIFU
High intensity Focused Ultrasound / HIFUDr. Muhammad Saifullah
 
MANAGEMENT OF LARYNGEAL CANCER.pptx
MANAGEMENT OF LARYNGEAL CANCER.pptxMANAGEMENT OF LARYNGEAL CANCER.pptx
MANAGEMENT OF LARYNGEAL CANCER.pptxKarishmaMishra13
 
Anesthesia consideration for parotidectomy
Anesthesia  consideration for parotidectomyAnesthesia  consideration for parotidectomy
Anesthesia consideration for parotidectomyTayyab_khanoo9
 

Semelhante a Nasopharyngeal brachytherapy (20)

Management Carcinoma Nose & PNS
 Management Carcinoma Nose & PNS Management Carcinoma Nose & PNS
Management Carcinoma Nose & PNS
 
Ca Maxilla - Radiation Therapy
Ca Maxilla - Radiation Therapy Ca Maxilla - Radiation Therapy
Ca Maxilla - Radiation Therapy
 
Ca external and middle ear staging to management1
Ca external and middle ear staging to management1Ca external and middle ear staging to management1
Ca external and middle ear staging to management1
 
Lacrimal sac surgery
Lacrimal sac surgeryLacrimal sac surgery
Lacrimal sac surgery
 
journal presentation on traumatic Tympanic membrane perforations.pptx
journal presentation on traumatic Tympanic membrane perforations.pptxjournal presentation on traumatic Tympanic membrane perforations.pptx
journal presentation on traumatic Tympanic membrane perforations.pptx
 
JC PRESENTATION.pptx journey of a oh yeahh
JC PRESENTATION.pptx journey of a oh yeahhJC PRESENTATION.pptx journey of a oh yeahh
JC PRESENTATION.pptx journey of a oh yeahh
 
Salivary gland tumors
Salivary gland tumors Salivary gland tumors
Salivary gland tumors
 
Neck node management
Neck node managementNeck node management
Neck node management
 
Head Neck Interstitial Brachy.pptx
Head Neck Interstitial Brachy.pptxHead Neck Interstitial Brachy.pptx
Head Neck Interstitial Brachy.pptx
 
MOULD BRACHYTHERAPY LIP
MOULD BRACHYTHERAPY LIPMOULD BRACHYTHERAPY LIP
MOULD BRACHYTHERAPY LIP
 
Seminar on para nasal sinus and it's prosthodontics implications
Seminar on para nasal sinus and it's prosthodontics implications Seminar on para nasal sinus and it's prosthodontics implications
Seminar on para nasal sinus and it's prosthodontics implications
 
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...
IMRT Combined with Cetuximab for Locally Recurrent Nasopharyngeal Carcinoma C...
 
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGY
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGYCARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGY
CARCINOMA MAXILLARY SINUS MANAGEMENT RADIATION ONCOLOGY
 
Ca oral cavity management
Ca oral cavity managementCa oral cavity management
Ca oral cavity management
 
Neonatal nasal obstruction final
Neonatal nasal obstruction finalNeonatal nasal obstruction final
Neonatal nasal obstruction final
 
Radiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumoursRadiotherapy plan evaluation in brain tumours
Radiotherapy plan evaluation in brain tumours
 
High intensity Focused Ultrasound / HIFU
High intensity Focused Ultrasound / HIFUHigh intensity Focused Ultrasound / HIFU
High intensity Focused Ultrasound / HIFU
 
MANAGEMENT OF LARYNGEAL CANCER.pptx
MANAGEMENT OF LARYNGEAL CANCER.pptxMANAGEMENT OF LARYNGEAL CANCER.pptx
MANAGEMENT OF LARYNGEAL CANCER.pptx
 
Anesthesia consideration for parotidectomy
Anesthesia  consideration for parotidectomyAnesthesia  consideration for parotidectomy
Anesthesia consideration for parotidectomy
 
48th Publication- JDHR-3rd Name.pdf
48th Publication- JDHR-3rd Name.pdf48th Publication- JDHR-3rd Name.pdf
48th Publication- JDHR-3rd Name.pdf
 

Mais de Ashutosh Mukherji

Mgmt vulva and vagina cancers
Mgmt vulva and vagina cancersMgmt vulva and vagina cancers
Mgmt vulva and vagina cancersAshutosh Mukherji
 
Debate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancerDebate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancerAshutosh Mukherji
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationAshutosh Mukherji
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersAshutosh Mukherji
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updatesAshutosh Mukherji
 
Screening in colorectal cancers dr. ashutosh
Screening in colorectal cancers  dr. ashutoshScreening in colorectal cancers  dr. ashutosh
Screening in colorectal cancers dr. ashutoshAshutosh Mukherji
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Ashutosh Mukherji
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherjiAshutosh Mukherji
 
Radiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignanciesRadiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignanciesAshutosh Mukherji
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutoshAshutosh Mukherji
 

Mais de Ashutosh Mukherji (20)

Mgmt vulva and vagina cancers
Mgmt vulva and vagina cancersMgmt vulva and vagina cancers
Mgmt vulva and vagina cancers
 
High risk early stage ec
High risk early stage ecHigh risk early stage ec
High risk early stage ec
 
Radiotherapy sarcomas
Radiotherapy sarcomas Radiotherapy sarcomas
Radiotherapy sarcomas
 
Debate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancerDebate: CCRT in Pancreatic cancer
Debate: CCRT in Pancreatic cancer
 
Rectal cancer debate: Chemoradiation
Rectal cancer debate: ChemoradiationRectal cancer debate: Chemoradiation
Rectal cancer debate: Chemoradiation
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck Cancers
 
Sarcoma brachytherapy updates
Sarcoma brachytherapy updatesSarcoma brachytherapy updates
Sarcoma brachytherapy updates
 
Crc rt updates ethiopia
Crc rt updates   ethiopiaCrc rt updates   ethiopia
Crc rt updates ethiopia
 
Icru 71 electrons
Icru 71 electrons Icru 71 electrons
Icru 71 electrons
 
Contouring rectal cancers
Contouring rectal cancersContouring rectal cancers
Contouring rectal cancers
 
Lung plan evaluation
Lung plan evaluationLung plan evaluation
Lung plan evaluation
 
Biomarkers in gliomas
Biomarkers in gliomasBiomarkers in gliomas
Biomarkers in gliomas
 
Screening in colorectal cancers dr. ashutosh
Screening in colorectal cancers  dr. ashutoshScreening in colorectal cancers  dr. ashutosh
Screening in colorectal cancers dr. ashutosh
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017
 
Srs debate dr. ashutosh mukherji
Srs debate   dr. ashutosh mukherjiSrs debate   dr. ashutosh mukherji
Srs debate dr. ashutosh mukherji
 
IMRT in pancreas
IMRT in pancreasIMRT in pancreas
IMRT in pancreas
 
Stomach adjuvant rt
Stomach adjuvant rtStomach adjuvant rt
Stomach adjuvant rt
 
IHC in breast CA
IHC in breast CAIHC in breast CA
IHC in breast CA
 
Radiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignanciesRadiotherapy in paediatrics - late effects and second malignancies
Radiotherapy in paediatrics - late effects and second malignancies
 
Personalised medicine in rt dr. ashutosh
Personalised medicine in rt   dr. ashutoshPersonalised medicine in rt   dr. ashutosh
Personalised medicine in rt dr. ashutosh
 

Último

Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthGokuldas Hospital
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 

Último (20)

Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 

Nasopharyngeal brachytherapy

  • 1. Nasopharyngeal Brachytherapy Dr. Ashutosh Mukherji Associate Professor Department of Radiotherapy, Regional Cancer Centre, JIPMER
  • 2. INTRODUCTION • Cancer of the nasopharynx is relatively uncommon in Western countries (0.5-2/1,00,000/yr), but more frequent in parts of Asia (30-80/1,00,000/yr) and North Africa (8-12/100,000/yr). • Mostly Inoperable, spread early to cervical lymph nodes, distant metastases is fairly well known. • Main prognosis factors are the local extension of the tumours (invasion of the base of skull and paralysis of the cranial nerves) and lymph node metastasis. 2
  • 3. ANATOMY……. 3 • The nasopharyngeal cavity communicates anteriorly with the nasal cavities through the choanae and inferiorly with the oropharynx. • The sphenoid body limits it superiorly, the first two vertebrae posteriorly, and the soft palate inferiorly. • The Eustachian tubes open into its lateral walls, in front of the fossa of Rosenmüller.
  • 4. INDICATIONS • Brachytherapy applications of the nasopharynx are restricted to – Boost for minimal residual local disease after external irradiation – Salvage therapy for well-circumscribed and superficial local recurrences limited to the nasopharyngeal cavity without involvement of the underlying bone or extending to oropharynx or nasal cavities 4
  • 5. • Nasopharynx deeply situated and surrounded by bone, vessels and nerves  usually endocavitary techniques can be performed. • CTV thickness should not exceed 10 mm • Tumours extending into the nasal cavities or the oropharynx should not be accepted for brachytherapy. 5
  • 6. TARGET VOLUME • The PTV defined by endoscopy, CT-Scan and MRI. • Most tumours are situated at the roof of the nasopharynx. 6 In central tumours, the CTV may include both roof and lateral walls. In well-lateralised tumours, CTV will include the roof and one lateral wall. In most cases, the depth of PTV does not exceed 10 mm.
  • 7. TECHNIQUES APPLIED • CUSTOMISED MOULD • ROTTERDAM NASOPHARYNGEAL APPLICATOR • MASSACHUSETTS GENERAL HOSPITAL TECHNIQUE • TRANSNASAL PERMANENT INTERSTITIAL IMPLANTS 7
  • 8. CUSTOMISED MOULD TECHNIQUE • Sagittally oriented plastic tubes are fixed on the surface of a rigid acrylic applicator, made from an individual impression of the nasopharyngeal cavity. • Procedure is therefore performed under neuroleptic analgesia • Nasal secretions are suctioned and the mucous membranes anaesthetised with 5% xylocaine spray to avoid gag reflex or pain. • First rubber catheters are passed through both nostrils and brought out of the mouth; the oral ends of these are tied to a dummy applicator coated with silicone paste. 8
  • 9. • This paste coated dummy applicator is pulled into the nasopharynx and paste forms an impression of the naspharyngeal cavity. • Then from this impression a negative POP mould is prepared from which the actual acrylic mould is made with 2-5 mm thick walls. • Boundaries of the tumour are highlighted in ink and source position that will provide optimal coverage of the lesion are indicated with sagittal lines. • Spacing between sources varies from 10 to 15 mm. In average patients, the rule for catheter implantation is 2 catheters per wall or 3 catheters for 2 walls or 4 catheters for 3 walls (roof and 2 walls) 9
  • 10. 10
  • 11. ROTTERDAM APPLICATOR • Is made of soft silicone • Well tolerated by patient • Insertion procedure is same as for customised mould • The applicator can remain in situ for the duration of the treatment, from 2 to 6 days. • The two silicone tubes, can accommodate standard 6 French afterloading catheters. • The legs of the applicator sort through the nostrils and are fixed with a silicone bridge, pushed against the nasal septum. 11
  • 12. 12
  • 13. MASSACHUSETTS GENERAL HOSPITAL TECHNIQUE • This technique uses two paediatric endotracheal tubes with inner and outer diameter of 5 and 6.8 mm, respectively. They can be afterloaded each with 20-mg radium-equivalent caesium 137 slugs or stepping source PDR or HDR afterloaders. • After topical anaesthesia endotracheal tubes are introduced into the nasopharynx through the nostrils and under fluoroscopic control, the distal tip of the dummy sources are placed at the free edge of the soft palate posteriorly and at the posterior wall of the maxillary sinus anteriorly. • An inflated balloon, attached to the distal end of the endotracheal tube, is used to anchor the tubes and to create a distance between the radiation sources and the nasopharyngeal vault to obtain a better depth dose. 13
  • 14. TRANSNASAL PERMANENT INTERSTITIAL IMPLANTS • Using fibre-optic endoscopy and under direct visualisation, hollow after- loading needles are introduced into the nasal passages and are advanced through the posterior choanae, and inserted into the mucosal surface. • Radioactive I-125 seeds are then introduced submucosally through these needles, and the needles are withdrawn. 14
  • 15. • The dose prescribed to an isodose covering the surface of the underlying bone, at 5 - 10 mm from the mucosal surface. • Dose distribution optimized when possible so that the reference isodose follows the bone surface. 15
  • 16. • Brachytherapy used to deliver BOOST dose to a small volume after a full course of external beam radiation therapy. • In LDR brachy, the active source is tailored to the nasopharynx proper that is to the distance between the ‘Node of Rouviere’ (at the level of the C-I vertebral body) and the pterygoid plates. The Ir-192 source is removed after a dose of 11 Gy is delivered to the nasopharynx “tumour tissue” (TT) point. • For HDR, a boost dose of 9 Gy in 3 fractions of 3 Gy each is delivered with a minimum interval of 6 hours between fractions prescribed as described in previous slides. 16
  • 17. DOSES PRESCRIBED • Wang delivered with LDR afterloading intracavitary implant 7 - 12 Gy at 5 mm below the mucosa. • Levendag et al. deliver after a rest period of 1 - 2 weeks, a boost dose to the primary site with HDR brachytherapy, with two 3 Gy fractions per day at 6 hour interval. Total of fractions is 6 (after 60 Gy external beam irradiation) for T1 - 3 tumours, and 4 (after 70 Gy external beam irradiation) for T4 tumours. • For recurrent tumour recurring, 60 Gy is delivered in roughly 6 days with a LDR technique 17
  • 18. 18
  • 19. RESULTS • Since 1974, at Massachusetts General Hospital, afterloading intracavitary implant has been carried out as a routine procedure to deliver a dose of 7- 12 Gy as a boost to the nasopharynx for most T1 and T2 and occasionally T3 lesions 19 5 year survival rates in MGH in nasopharyngeal cancers
  • 20. RESULTS • At Rotterdam, in a prospective study of 41 patients treated with 60-70 Gy external beam radiation therapy and 12 - 18 Gy HDR brachytherapy boost, the 5-year local relapse free survival rate of T1 - 2 cancer patients (n = 29) was 96% versus 57% for T4 cancer patients (n = 12) (p = 0.002) 20 5 year actuarial survival rates in MGH in recurrent nasopharyngeal cancers
  • 21. 21
  • 25. RESULTS • 18–24% of patients with nasopharyngeal carcinoma develop local recurrences • Brachytherapy is an important modality for treatment of localised small recurrences. • Other modalities are: – Cyberknife RadioSurgery – SBRT – IMRT • The period elapsed before development of local recurrence is a significant factor influencing disease-free survival times. 25
  • 26. Causes of relapse in Ca Nasopharynx Failure= 192/610 (31%) Local Failure ONLY= 52% Distance metastasis=27% Death= 156/610 Cause of death: Local Relapse only= 44% Distance mets= 28% Local control after relapse improves survival Sun JA et al, Asian Pacific J 2007
  • 27. Surgery for Rec Nasopharynx - ONLY few prospective reports - Skull base/ bone erosion & carotid artery erosion not considered for surgery - 5-Yr OS: 40-60% - 20% palatal fistula
  • 28. 28
  • 29. Liu et al. Radiation Oncology 2013 SBRT: persistent Nasopharyngeal Ca
  • 30. -No difference in maximum spinal cord dose and mean parotid doses between HDR & CK boost plans; In IMRT plan, higher ipsi-lateral parotid dose Comparison of three plans (Dose: 24 Gy/6#) IMRT boost HDR boost CK boost Spinal cord Dmax (Gy) 7.4 1.2 1.5 Ipsi-lateral parotid Mean dose (Gy) 8.3 3.1 2.1 Conta-lateral parotid Mean dose (Gy) 3.7 1.4 1.7 (n=11) Dutta et al; CK Society meeting San Francisco 2010
  • 31. 31 • Study from Hong Kong • 34 patients with locally persistent NPC who were treated during 1992–2000 with HDR intracavitary brachytherapy were analyzed retrospectively. All patients had T2b disease at initial diagnosis. • An improvement in the 5-year actuarial local failure-free survival rate (brachytherapy group vs. ERT group: 96.9% vs. 81.5%; P 0.024), the disease specific survival rate (84.5% vs. 68.1%; P 0.021), and the overall survival rate (78.3% vs. 63.1%; P 0.034) was seen in the group with locally persistent NPC salvaged with brachytherapy.